-
Belite Bio Analysts See Potential For Stock Gains With Progress In Key Trials
Tuesday, March 18, 2025 - 11:09am | 431Read More...After Belite Bio Inc (NASDAQ:BLTE) reported results, its stock has been under pressure. The company reported its results amid an exciting earnings season. Here are some key analyst takeaways. HC Wainwright On Belite Bio Analyst Yi Chen maintained a Buy rating and price target of $100. Belite Bio...
-
Applied DNA Analyst Says Coronavirus Testing, Vaccine Work Could Drive Major Upside
Thursday, July 2, 2020 - 1:08pm | 425Read More...Shares of Applied DNA Sciences Inc (NASDAQ: APDN), which is in the race to develop a vaccine for the novel coronavirus, offer an attractive buying opportunity, according to H.C. Wainwright. The Applied DNA Analyst: Yi Chen initiated coverage of Applied DNA shares with a Buy rating and $18...
-
Inovio's HIV Vaccine Elicits High Response Rates In Phase 1 Trial
Thursday, May 25, 2017 - 12:15pm | 563Read More...Following the results release of an early-stage study of Pennvax-GP, Inovio Pharmaceuticals Inc (NASDAQ: INO)'s HIV vaccine, H.C. Wainwright noted that the vaccine elicited high T-cell and antibody immune responses in healthy and uninfected adults. The Trial Analysts Raghuram Selvaraju and Yi Chen...
-
HTG Molecular's Profiling System 'Requires Less But Delivers More'
Monday, August 22, 2016 - 10:18am | 356Read More...Rodman & Renshaw initiated coverage on HTG Molecular Diagnostics Inc (NASDAQ: HTGM) shares with a Buy rating. The brokerage has a price objective of $5 on the company's stock, citing that the molecular profiling system required less sample material to deliver more. Analysts Raghuram Selvaraju...
-
Galectin Therapeutics Still A Favorite Pick Of H.C. Wainwright Analysts
Monday, September 28, 2015 - 2:11pm | 296Read More...H.C. Wainwright reiterated a Buy rating and $7.00 price target on shares of Galectin Therapeutics Inc (NASDAQ: GALT) on Monday. The company announced last week that it had initiated a Phase 2a Psoriasis study. Shares of Galectin are down more than 1.4 percent on Monday trading. Late...
-
Galectin Therapeutics Could Triple On Fibrosis And Cirrhosis Treatment
Monday, September 21, 2015 - 10:13am | 341Read More...Shares of Galectin Therapeutics, Inc. (NASDAQ: GALT) have declined more than 32 percent year-to-date. HC Wainwright’s Yi Chen has initiated coverage of Galectin Therapeutics with a Buy rating and $7 price target. The company is developing a treatment for nonalcoholic steatohepatitis...
-
Biocept Could Double On Liquid Biopsy Leadership: H.C. Wainwright
Wednesday, August 19, 2015 - 8:26am | 262Read More...In illiquid pre-market trading, Biocept Inc (NASDAQ: BIOC) was indicated 6 percent higher at $2.08 following a bullish note from H.C. Wainwright & Co. analyst Yi Chen. Chen, who has a Ph.D. in biochemistry, is optimistic on Biocept's liquid biopsy technology, which he said provides...
-
Aegis Capital Reiterates Buy On CytRx As Stock Soars 17%
Tuesday, January 6, 2015 - 4:20pm | 236Read More...Aegis Capital issued an update on CytRx Corporation (NASDAQ: CYTR) Tuesday and reiterated its Buy rating and $12 price target. Analyst Yi Chen noted that the company announced “positive interim results from the ongoing Phase 2 clinical trial with aldoxorubicin for the treatment of...
-
Aegis Capital Downgrades Recro Pharma, Says Investors Should Be Cautious
Tuesday, December 9, 2014 - 3:59pm | 207Read More...Aegis Capital downgraded Recro Pharma Inc (NASDAQ: REPH) Tuesday from Buy to Hold and did not set a price target. Analyst Yi Chen noted that “Recro Pharma started a Phase 2 clinical trial of Dex-IN, its proprietary intranasal formulation of dexmedetomidine, in late October 2014 in the...
-
Aegis Capital Downgrades Alcobra Following Q3 Results
Monday, November 17, 2014 - 6:19pm | 170Read More...On Monday, analysts at Aegis Capital downgraded shares of Alcobra Ltd (NASDAQ: ADHD) from Buy to Hold without a price target. Yi Chen stated, "In view of the uncertainty from the FDA as to whether Alcobra can submit an NDA with data from one additional Phase 3 adult ADHD trial and data...
